methylprednisolone has been researched along with Lymphoma, Mantle-Cell in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, L; Li, JY; Shi, K; Wang, L; Xia, Y; Xu, W; Zhu, HY | 1 |
| Jin, JG | 1 |
| Lubas, A; Mróz, A; Niemczyk, S; Smoszna, J | 1 |
| Archer, CD; Catovsky, D; Chau, I; Cunningham, D; Gill, K; Harries, M; Hill, M; Koh, DM; Norman, AR; Prior, Y; Ross, PJ; Uzzell, M; Wotherspoon, A | 1 |
| Helfgott, SM; Todd, DJ | 1 |
1 trial(s) available for methylprednisolone and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hodgkin Disease; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Male; Methylprednisolone; Middle Aged; Recurrence; Survival Rate | 2003 |
4 other study(ies) available for methylprednisolone and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
[High-dose methylprednisolone with Rituximab and fresh frozen plasma in the treatment of six patients with B-cell lymphoproliferative disorders harboring TP53 abnormalities].
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Methylprednisolone; Rituximab; Tumor Suppressor Protein p53 | 2019 |
High-dose methylprednisolone is effective in treating radiation-induced refractory haemorrhagic cystitis.
Topics: Aluminum Oxide; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Combined Modality Therapy; Cyclophosphamide; Cystitis; Doxorubicin; Estrogens; Etoposide; Fluid Therapy; Hematuria; Humans; Hyperbaric Oxygenation; Immunosuppressive Agents; Lymphatic Irradiation; Lymphatic Metastasis; Lymphoma, Mantle-Cell; Male; Methylprednisolone; Middle Aged; Prednisone; Radiation Injuries; Radiotherapy, Conformal; Recurrence; Rituximab; Salvage Therapy; Vincristine | 2014 |
Membranoproliferative glomerulonephritis, mantle cell lymphoma infiltration, and acute kidney injury.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents; Cyclophosphamide; Glomerulonephritis, Membranoproliferative; Humans; Immunosuppressive Agents; Lymphoma, Mantle-Cell; Methylprednisolone; Middle Aged; Prednisone; Renal Dialysis | 2013 |
Serum sickness following treatment with rituximab.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Therapy, Combination; Humans; Injections, Intra-Articular; Lymphoma, Mantle-Cell; Male; Methylprednisolone; Prednisolone; Rituximab; Serum Sickness; Treatment Outcome | 2007 |